MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. Its lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. The company is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. is headquartered in Chicago, Illinois.